欧洲前列腺癌有组织风险分层早期检测项目模型
本文基于文献综述与专家共识,提出一种有组织的人群前列腺癌早期检测风险分层算法:先进行基于风险的前列腺特异性抗原(PSA)检测,再以风险计算器(RC)进行多变量风险分层,中高危男性接受前列腺磁共振成像(MRI),结合RC与MRI结果选择活检,低危男性进入基于风险的安全网随访。该策略尚未前瞻性验证,但有望减少不必要的活检与过度诊断。
要点
- 以风险计算器进行多变量分层,中高危者再行前列腺MRI。
- 结合RC与MRI结果选择活检,低危者进入个体化PSA间期随访。
- 该算法尚未前瞻性验证,但可减少不必要活检与过度诊断。
核心结论
- 提出一种基于风险分层的有组织人群前列腺癌早期检测算法,尚需前瞻性验证。
研究设计与样本
- 专家共识基于非系统性文献综述,检索Medline/PubMed、Cochrane Library、ClinicalTrials.gov、ISRCTN Registry及欧洲泌尿外科学会前列腺癌指南。
主要发现
- 当前文献与指南指向以风险为基础的PSA检测启动,随后用风险计算器进行多变量风险分层。
- 中高危男性接受前列腺MRI,结合RC与MRI结果选择活检,低危男性进入基于风险的安全网随访。
关键数值与推荐
- 算法步骤:风险基于PSA检测→风险计算器多变量分层→中高危者前列腺MRI→结合RC与MRI选择活检→低危者个体化PSA间期检测及必要时重复MRI。
- 不同风险分层工具的使用可根据当地可及性调整。
临床怎么用
- 临床可参考该算法对有组织人群进行前列腺癌早期检测,结合当地资源选择风险计算器与MRI。
- 低危男性应进入基于风险的安全网,进行个体化PSA间期检测及必要时重复MRI。
局限性
- 该算法基于专家共识与非系统性文献综述,未经最高级别证据证实。
- 所提策略尚未进行前瞻性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Overdiagnosis as the argument to stop prostate cancer (PCa) screening is less valid since the introduction of new technologies such as risk calculators (RCs) and magnetic resonance imaging (MRI). These new technologies result in fewer unnecessary biopsy procedures and fewer cases of both overdiagnosis and underdetection. Therefore, we can now adequately respond to the growing and urgent need for a structured risk assessment to detect PCa early. OBJECTIVE: To provide expert discussion on the existing evidence for a previously published risk-stratified strategy regarding an organised population-based early detection programme for PCa. EVIDENCE ACQUISITION: The proposed algorithm for early detection of PCa emerged from expert consensus by the authors based on available evidence derived from a nonsystematic review of the current literature using Medline/PubMed, Cochrane Library database, ClinicalTrials.gov, ISRCTN Registry, and the European Association of Urology guidelines on PCa. EVIDENCE SYNTHESIS: Although not confirmed by the highest level of evidence, current literature and guidelines point towards an algorithm for early detection of PCa that starts with risk-based prostate-specific antigen (PSA) testing, followed by multivariable risk stratification with RCs. All men who are classified to be at intermediate and high risk are then offered prostate MRI. The combined data from RCs and MRI results can be used to select men for prostate biopsy. Low-risk men return to a risk-based safety net that includes individualised PSA-interval tests and, if necessary, repeated MRI. Depending on local availability, the use of the different risk stratification tools may be adapted. CONCLUSIONS: We present a risk-stratified algorithm for an organised population-based early detection programme for clinically significant PCa. Although the proposed strategy has not yet been analysed prospectively, it exploits and may even improve the most important available benefits of "PSA-only" screening studies, while at the same time reduces unnecessary biopsies and overdiagnosis by using new risk stratification tools. PATIENT SUMMARY: This paper presents a personalised strategy that enables selective early detection of prostate cancer by combining prostate-specific antigen (interval) testing' prediction models (risk calculators), and magnetic resonance imaging scans. This will likely lead to reduced prostate cancer-related morbidity and mortality, while reducing the need for prostate biopsy and limiting overdiagnosis.
引用
- Van Poppel H, Hogenhout R, Albers P, et al. A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer. Eur Urol Oncol. 2021. PMID: 34364829. doi:10.1016/j.euo.2021.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。